ApprovedFDA approval

Tauklarify (florquinitau F 18)

Cerveau Technologies (Lantheus) (LNTH)

Marketer take

A tau PET agent for patients being evaluated for Alzheimer's disease, so memory clinics, neurologists and imaging centers are the audience, and it competes directly with Tauvid.

Sponsor company
Cerveau Technologies (Lantheus) (LNTH)
Indication
To be used for positron emission tomography of the brain in adults with cognitive impairment who are being evaluated for Alzheimer disease to identify patients with tau neurofibrillary tangle pathology
Therapeutic area
Diagnostic imaging, Neurology
Event
FDA approval
Date
Aug 13, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move